Group items tagged

The Toronto Region Immigrant Employment Council (TRIEC) is pleased to announce today's appointment of Gordon M. Nixon, president and chief executive officer of RBC, as Chair, and Zabeen Hirji, chief human resources officer of RBC, as Co-Chair of TRIEC.

As top executives at one of the largest financial institutions in North America, Gord Nixon and Zabeen Hirji are key ambassadors to articulate how Canadian companies can benefit from the international experience and networks, language skills and cultural knowledge that skilled immigrants bring with them to Canada."

Nixon has for years been a champion for promoting diversity in Canadian communities and of leveraging skilled immigrant talent as a driver of Canadian innovation and prosperity. Nixon is chairman of the Canadian Council of Chief Executives and chairman of MaRS Discovery District. In 2007, Nixon was invested into the Order of Ontario and was named Canada's Outstanding CEO of the Year.

Benecaid has named Jonathan Graff to Co-President, a new role in which he will share senior executive responsibilities with Marla Schwartz, who has been Benecaid's President since 2005.

Benecaid is a health benefits administrator that provides cost-effective, customized plan management for small and medium-sized employers and the self-employed. Its innovative approach has resulted in revenue growth of nearly 5,000 per cent over the last five years. Benecaid was ranked in the top 10 of Profit 100's Fastest Growing Canadian Companies in 2009.

The Ivey Centre for Health Innovation and Leadership was launched this year with a $5-million push from the Canadian government. The latest Ivey initiative has the goal of bringing students together with experts from the science and business sectors, with the ultimate goal of better identifying and commercializing health technologies.Dr. Kellie Leitch, a Hospital for Sick Children orthopedic surgeon, is the first executive director of the centre, which is based at Western.

She is sitting in the basement of MaRS, a scientific hub of activity in downtown Toronto where labs, business and major Toronto teaching hospitals are brought together under one roof.

The Ivey centre will focus on giving the educational capability to our students so they become really well educated in innovation and commercialization, so we can keep things here at home in Canada and grow those products."

GORDON NIXON, ROYAL BANK OF CANADA

chairman of the Canadian Council of Chief Executives and chairman of MaRS, a not-for-profit organization that connects science, business and capital

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.